 Connection
Marilyn Manco-Johnson to Factor VIII
This is a "connection" page, showing publications Marilyn Manco-Johnson has written about Factor VIII.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
5.884 |
|
|
|
-
Manco-Johnson MJ, Lundin B, Funk S, Peterfy C, Raunig D, Werk M, Kempton CL, Reding MT, Goranov S, Gercheva L, Rusen L, Uscatescu V, Pierdominici M, Engelen S, Pocoski J, Walker D, Hong W. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost. 2017 11; 15(11):2115-2124.
Score: 0.506
-
Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017 04 27; 129(17):2368-2374.
Score: 0.483
-
Tiede A, Oldenburg J, Lissitchkov T, Knaub S, Bichler J, Manco-Johnson MJ. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia. 2016 May; 22(3):374-80.
Score: 0.444
-
Branchford BR, Ruegg K, Villalobos-Menuey E, Jacobson LJ, Di Paola JA, Manco-Johnson M. FVIII/VWF ratio is not a reliable predictor of VWD in children. Pediatr Blood Cancer. 2014 May; 61(5):936-9.
Score: 0.387
-
Manco-Johnson MJ, Kempton CL, Reding MT, Lissitchkov T, Goranov S, Gercheva L, Rusen L, Ghinea M, Uscatescu V, Rescia V, Hong W. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013 Jun; 11(6):1119-27.
Score: 0.374
-
Gill JC, Shapiro A, Valentino LA, Bernstein J, Friedman C, Nichols WL, Manco-Johnson M. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease. Haemophilia. 2011 Nov; 17(6):895-905.
Score: 0.323
-
Manco-Johnson MJ. Advances in the care and treatment of children with hemophilia. Adv Pediatr. 2010; 57(1):287-94.
Score: 0.295
-
Manco-Johnson M. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice. Haemophilia. 2007 Sep; 13 Suppl 2:4-9.
Score: 0.251
-
Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007 Aug 09; 357(6):535-44.
Score: 0.250
-
Manco-Johnson M. Hemophilia management: optimizing treatment based on patient needs. Curr Opin Pediatr. 2005 Feb; 17(1):3-6.
Score: 0.210
-
Manco-Johnson MJ. Update on treatment regimens: prophylaxis versus on-demand therapy. Semin Hematol. 2003 Jul; 40(3 Suppl 3):3-9.
Score: 0.188
-
Warren BB, Moyer GC, Manco-Johnson MJ. Hemostasis in the Pregnant Woman, the Placenta, the Fetus, and the Newborn Infant. Semin Thromb Hemost. 2023 Jun; 49(4):319-329.
Score: 0.183
-
Manco-Johnson MJ, Warren BB. Long-term prophylaxis: what are our options and how to define success? Hematology Am Soc Hematol Educ Program. 2022 12 09; 2022(1):579-585.
Score: 0.181
-
Manco-Johnson MJ, Warren BB, Buckner TW, Funk SM, Wang M. Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate). Haemophilia. 2021 Feb; 27 Suppl 3:87-95.
Score: 0.158
-
Maher KN, Gibson E, Warren BB, Funk SM, Shearer R, Buckner TW, Wang M, Manco-Johnson MJ, Ng CJ. Prophylaxis for children with moderate hemophilia: Use of a guideline to increase early initiation. Pediatr Blood Cancer. 2021 01; 68(1):e28577.
Score: 0.155
-
Manco-Johnson MJ, Nuss R, Jacobson LJ. Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. J Lab Clin Med. 2000 Jul; 136(1):74-9.
Score: 0.153
-
Warren BB, Thornhill D, Stein J, Fadell M, Ingram JD, Funk S, Norton KL, Lane HD, Bennett CM, Dunn A, Recht M, Shapiro A, Manco-Johnson MJ. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Adv. 2020 06 09; 4(11):2451-2459.
Score: 0.152
-
Nuss R, Jacobson L, Hathaway WE, Manco-Johnson M. Evidence for antiphospholipid antibodies in hemophilic children with factor VIII inhibitors. Recombinate PUP Study Group. Thromb Haemost. 1999 Nov; 82(5):1559-60.
Score: 0.146
-
Warren BB, Jacobson L, Kempton C, Buchanan GR, Recht M, Brown D, Leissinger C, Shapiro AD, Abshire TC, Manco-Johnson MJ. Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. Haemophilia. 2019 Sep; 25(5):867-875.
Score: 0.141
-
Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
Score: 0.115
-
Antun A, Monahan PE, Manco-Johnson MJ, Callaghan MU, Kanin M, Knoll C, Carpenter SL, Davis JA, Guerrera MF, Kruse-Jarres R, Ragni MV, Witmer C, McCracken CE, Kempton CL. Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study. J Thromb Haemost. 2015 Nov; 13(11):1980-8.
Score: 0.110
-
Nakar C, Manco-Johnson MJ, Lail A, Donfield S, Maahs J, Chong Y, Blades T, Shapiro A. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia. 2015 May; 21(3):365-373.
Score: 0.105
-
Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia. 2014 Mar; 20(2):230-7.
Score: 0.097
-
Di Paola J, Lethagen S, Gill J, Mannucci P, Manco-Johnson M, Bernstein J, Nichols WL, Bergman GE. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery. Haemophilia. 2011 Sep; 17(5):752-8.
Score: 0.082
-
Goldenberg NA, Hathaway WE, Jacobson L, McFarland K, Manco-Johnson MJ. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A. Haemophilia. 2006 Nov; 12(6):605-14.
Score: 0.059
-
Kreuz W, Gill JC, Rothschild C, Manco-Johnson MJ, Lusher JM, Kellermann E, Gorina E, Larson PJ. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost. 2005 Mar; 93(3):457-67.
Score: 0.053
-
Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med. 2004 Sep 09; 351(11):1081-8.
Score: 0.051
-
Han JH, Dupervil B, Mahajerin A, Kulkarni R, Manco-Johnson M, Thornburg C. Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia. Blood Adv. 2024 06 11; 8(11):2707-2717.
Score: 0.050
-
Manco-Johnson MJ, Riske B, Kasper CK. Advances in care of children with hemophilia. Semin Thromb Hemost. 2003 Dec; 29(6):585-94.
Score: 0.048
-
Link KG, Stobb MT, Sorrells MG, Bortot M, Ruegg K, Manco-Johnson MJ, Di Paola JA, Sindi SS, Fogelson AL, Leiderman K, Neeves KB. A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A. J Thromb Haemost. 2020 02; 18(2):306-317.
Score: 0.036
-
Onasoga-Jarvis AA, Leiderman K, Fogelson AL, Wang M, Manco-Johnson MJ, Di Paola JA, Neeves KB. The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models. PLoS One. 2013; 8(11):e78732.
Score: 0.024
-
Gupta S, Siddiqi AE, Soucie JM, Manco-Johnson M, Kulkarni R, Lane H, Ingram-Rich R, Gill JC. The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia. Br J Haematol. 2013 May; 161(3):424-33.
Score: 0.023
-
Ng C, Silliman CC, Pearl G, Smith W, Manco-Johnson M, Wang M. Treatment of refractory hemorrhage with Factor XIII in a patient with hemophilia A with inhibitor. Pediatr Blood Cancer. 2013 Jul; 60(7):E23-5.
Score: 0.023
-
Bernard TJ, Fenton LZ, Apkon SD, Boada R, Wilkening GN, Wilkinson CC, Soep JB, Miyamoto SD, Tripputi M, Armstrong-Wells J, Benke TA, Manco-Johnson MJ, Goldenberg NA. Biomarkers of hypercoagulability and inflammation in childhood-onset arterial ischemic stroke. J Pediatr. 2010 Apr; 156(4):651-6.
Score: 0.018
-
Soucie JM, Richardson LC, Evatt BL, Linden JV, Ewenstein BM, Stein SF, Leissinger C, Manco-Johnson M, Sexauer CL. Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males. Transfusion. 2001 Mar; 41(3):338-43.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|